AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
179.94
+1.58 (+0.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close178.36
Open177.12
Bid179.05 x 1200
Ask180.00 x 800
Day's Range176.66 - 179.99
52 Week Range153.56 - 201.23
Volume1,865,312
Avg. Volume4,778,670
Market Cap119.84B
Beta1.70
PE Ratio (TTM)66.89
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield5.28 (2.99%)
Ex-Dividend Date2018-05-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amgen's migraine treatment focuses on huge un-met need, s...
    CNBC Videos6 days ago

    Amgen's migraine treatment focuses on huge un-met need, s...

    Michael Yee, Jefferies, discusses what Amgen’s new migraine treatment means for the company and the pharma space.

  • FDA approves new migraine-prevention drug
    CNBC Videos6 days ago

    FDA approves new migraine-prevention drug

    CNBC's Meg Tirrell reports on the newest class of migraine drugs called Aimovig, aproved by the FDA to treat powerful headaches.

  • Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
    Zacks16 hours ago

    Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

    Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

  • Forbes23 hours ago

    New Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little Value

    Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.

  • Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
    Investor's Business Daily2 days ago

    Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene

    Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist2 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Amgen's Label Expansion Application for Prolia Gets FDA Nod
    Zacks2 days ago

    Amgen's Label Expansion Application for Prolia Gets FDA Nod

    Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

  • Benzinga2 days ago

    Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...

  • The Wall Street Journal2 days ago

    New Migraine Drugs Offer Hope to Sufferers

    Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.

  • Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
    American City Business Journals3 days ago

    Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)

    Northern California showed itself to be an accommodating and receptive host for the 13th annual Amgen Tour of California.

  • Company News For May 21, 2018
    Zacks3 days ago

    Company News For May 21, 2018

    Companies in the news are: PYPL,AMGN,TTD,CBS

  • Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
    Zacks3 days ago

    Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

    Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

  • TheStreet.com5 days ago

    CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

    After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.

  • CNBC6 days ago

    Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

    One Wall Street analyst predicts the anti-migraine category could be a $1 billion to $2 billion business over the next five years. Michael Yee, managing director at Jefferies, expects others companies to get into the migraine treatment sector. The anti-migraine drug Aimovig from Amgen AMGN and Novartis NVS could become a $1 billion to $2 billion business over the next five years, said a Wall Street analyst.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks6 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Investopedia6 days ago

    10 Stocks That Will Thrive On Buybacks

    Buyback Boost: Repurchases are more likely to bolster these stocks

  • Moody's6 days ago

    Novartis AG -- Moody's: Aimovig approval credit positive for Amgen and Novartis

    Moody's Investors Service commented that the recent US Food and Drug Administration (FDA) approval of Aimovig for chronic migraines is credit positive for the Amgen Inc. (Baa1 stable) and Novartis AG (Aa3 negative). For additional information, please see Moody's Issuer Comment available on www.moodys.com. This publication does not announce a credit rating action.

  • TheStreet.com6 days ago

    Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

    said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zacks6 days ago

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist6 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist6 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Benzinga6 days ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • Investopedia6 days ago

    Novartis, Amgen Get FDA Nod for Migraine Drug

    Novartis AG (ADR) ( NVS) today announced that it has received the necessary approval from the U.S. Food and Drug Administration (FDA) for its key drug Aimovig (erenumab) as a preventive treatment of migraine in adults. The drug works by blocking a compound called calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. The drug is available for self-administering once a month using Amgen Inc.’s ( AMGN) SureClick auto-injector. During the phase 2 and phase 3 clinical trials in patients with chronic and episodic migraine, the use of Aimovig resulted in significant decline in monthly migraine days.

  • The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers’ Stocks Are Rising
    Fortune6 days ago

    The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers’ Stocks Are Rising

    Aimovig apparently cuts migraine days significantly.

  • Reuters6 days ago

    U.S. FDA approves Amgen drug for prevention of migraines

    Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, Amgen spokeswoman Kristen Davis said.